Topics

bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress

16:05 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have β0/β0 ...

Other Sources for this Article

Investors:
bluebird bio
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com

Media:
bluebird bio
Jenn Snyder, 617-448-0281
jsnyder@bluebirdbio.com

NEXT ARTICLE

More From BioPortfolio on "bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress"

Quick Search

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...